COVID-19: UNICEF begins stockpiling of 520m syringes

COVID-19: UNICEF begins stockpiling of 520m syringes

Mexico is prepared to negotiate clauses around possible civil responsibility in cases of unwanted secondary effects of vaccines, both bilaterally with laboratories and with the multilateral, World Health Organization-backed COVID-19 vaccine facility, known as COVAX, ministry spokesman Arturo Rocha said on Tuesday. As the unprecedented scenario hastens the front-runners to breakneck speed, the task of the global distribution of the vaccine doses remains a formidable challenge. "We will need to move as quickly as the vaccines can be produced".

As various vaccine candidates make their way through different stages of global clinical trials at a record pace, it remains unclear who foots the bill if people in poor countries fall sick from treatments.

To note, the SII will likely price the vaccine at about $5.

Last week, the UAE Ministry of Health and Prevention approved Phase III trials of the Sputnik V vaccine. The deal is expected to support a minimum of 1 billion doses of NVX-CoV2373 for India and LMIC. He said that the foundation was working to ensure that developing countries have access to the vaccine "at the same time and at the same volumes" as wealthy countries.

The billion syringes come on top of the 620 million that UNICEF would purchase for other vaccination programmes against diseases such as measles and typhoid.

Gavi, the Vaccine Alliance that promotes global immunization programmes, will reimburse Unicef for the procurement of syringes and safety boxes, which will be used for the covid-19 Vaccine Global Access Facility (COVAX Facility) and for other Gavi-funded immunization programmes if necessary, Unicef said. The Pune, Maharashtra-based company has the capacity to make 60 to 70 million doses a month.

Serum Institute

UNICEF will further map out global distribution and storage plans for a future Covid-19 vaccine. Headquartered in Hyderabad, Bharat Bio is now developing a vaccine in association with the Indian Council of Medical Research, in addition to vaccine collaborations with the University of Wisconsin and Thomas Jefferson University.

Billionaire philanthropist Bill Gates has said India's research and vaccine manufacturing capabilities will help the world in fighting coronavirus.

On Aug 11, Russia became the first country across the globe that registered a vaccine against the coronavirus infection, Sputnik V. On Sept 9, Russian Healthcare Minister Mikhail Murashko said that the third phase of clinical trials of the vaccine started.

Developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in August, Sputnik V derives from human adenoviral vectors platform.

Presently, Sputnik V is in Phase III trial in Russian Federation on approximately 40,000 participants. While delving deep on upcoming challenges of vaccine distribution across the world, Bill Gates, during the Grand Challenges Annual Meeting 2020, said India as a country has made long strides when it comes to developing health infrastructure.